Pain Therapeutics Stock Price, News & Analysis (NASDAQ:PTIE)

$3.97 0.08 (2.06 %)
(As of 11/17/2017 02:27 PM ET)
Previous Close$3.97
Today's Range$3.84 - $3.99
52-Week Range$3.10 - $9.31
Volume65,147 shs
Average Volume780,086 shs
Market Capitalization$26.18 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12

About Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics logoPain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:PTIE
  • CUSIP: 69562K10
  • Web: www.paintrials.com
Debt:
  • Current Ratio: 12.08%
  • Quick Ratio: 12.08%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.72 per share
  • Price / Book: 2.31
Profitability:
  • Trailing EPS: ($1.84)
  • Net Income: ($14,850,000.00)
  • Return on Equity: -80.13%
  • Return on Assets: -75.65%
Misc:
  • Employees: 9
  • Outstanding Shares: 6,600,000
 

Frequently Asked Questions for Pain Therapeutics (NASDAQ:PTIE)

What is Pain Therapeutics' stock symbol?

Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."

When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?

Pain Therapeutics shares reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.

How were Pain Therapeutics' earnings last quarter?

Pain Therapeutics (NASDAQ:PTIE) released its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.40) EPS for the quarter. View Pain Therapeutics' Earnings History.

When will Pain Therapeutics make its next earnings announcement?

Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February, 16th 2018. View Earnings Estimates for Pain Therapeutics.

Who are some of Pain Therapeutics' key competitors?

Who are Pain Therapeutics' key executives?

Pain Therapeutics' management team includes the folowing people:

  • Remi Barbier, Chairman of the Board, President, Chief Executive Officer (Age 56)
  • Nadav Friedmann, Chief Medical and Operating Officer, Director (Age 72)
  • Michael Marsman Pharm.D., Senior Vice President - Regulatory Affairs
  • Robert Z. Gussin Ph.D., Independent Director (Age 77)
  • Michael J. O' Donnell Esq., Independent Director (Age 56)
  • Saira Ramasastry, Independent Director (Age 41)
  • Sanford R. Robertson, Independent Director (Age 85)
  • Patrick J. Scannon M.D., Ph.D., Independent Director (Age 67)

How do I buy Pain Therapeutics stock?

Shares of Pain Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pain Therapeutics' stock price today?

One share of Pain Therapeutics stock can currently be purchased for approximately $3.97.

How big of a company is Pain Therapeutics?

Pain Therapeutics has a market capitalization of $26.18 million. The biopharmaceutical company earns ($14,850,000.00) in net income (profit) each year or ($1.84) on an earnings per share basis. Pain Therapeutics employs 9 workers across the globe.

How can I contact Pain Therapeutics?

Pain Therapeutics' mailing address is 7801 N Capital of Texas Hwy Ste 260, AUSTIN, TX 78731-1192, United States. The biopharmaceutical company can be reached via phone at +1-512-5012444.


MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Pain Therapeutics (NASDAQ:PTIE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Sell (Score: 1.00)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Pain Therapeutics (NASDAQ:PTIE)

Price Target History for Pain Therapeutics (NASDAQ:PTIE)

Analysts' Ratings History for Pain Therapeutics (NASDAQ:PTIE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017GabelliDowngradeHold -> SellLowView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Pain Therapeutics (NASDAQ:PTIE)

Earnings by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Earnings History by Quarter for Pain Therapeutics (NASDAQ PTIE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/27/2017N/AView Earnings Details
11/1/2017Q3 2017($0.40)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.47)($0.64)ViewN/AView Earnings Details
4/25/2017Q1 2017($0.42)($0.42)ViewN/AView Earnings Details
10/20/2016Q316($0.63)($0.56)ViewN/AView Earnings Details
7/19/2016Q216($0.98)($0.49)ViewN/AView Earnings Details
5/5/2016Q1($0.70)($0.91)ViewN/AView Earnings Details
10/30/2014Q314($0.56)$89.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.49)ViewN/AView Earnings Details
5/6/2014Q1 14($0.42)($0.56)$1.96 millionViewN/AView Earnings Details
2/4/2014Q413($0.07)$5.04$2.00 million$35.24 millionViewN/AView Earnings Details
10/31/2013Q313($0.07)($0.14)$2.00 million$1.96 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.07)($0.07)$2.80 million$1.96 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.14)($0.56)$2.79 million$2.47 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pain Therapeutics (NASDAQ:PTIE)
Current Year EPS Consensus Estimate: $-2.2 EPS
Next Year EPS Consensus Estimate: $-2.6 EPS

Dividends

Dividend History by Quarter for Pain Therapeutics (NASDAQ PTIE)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$5.2512/13/201212/17/201212/24/2012
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Pain Therapeutics (NASDAQ PTIE)

Insider Ownership Percentage: 32.70%
Institutional Ownership Percentage: 36.31%
Insider Trades by Quarter for Pain Therapeutics (NASDAQ:PTIE)
Institutional Ownership by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Insider Trades by Quarter for Pain Therapeutics (NASDAQ PTIE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2013Sanford RobertsonDirectorBuy50,000$3.73$186,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pain Therapeutics (NASDAQ:PTIE)

Latest Headlines for Pain Therapeutics (NASDAQ PTIE)

Source:
DateHeadline
Should You Be Concerned About Pain Therapeutics Inc’s (PTIE) Shareholders?Should You Be Concerned About Pain Therapeutics Inc’s (PTIE) Shareholders?
finance.yahoo.com - November 15 at 7:42 AM
Pain Therapeutics (PTIE) Releases  Earnings ResultsPain Therapeutics (PTIE) Releases Earnings Results
www.americanbankingnews.com - November 2 at 5:19 PM
Pain Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Pain Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 2 at 7:58 AM
Pain Therapeutics Reports Third Quarter 2017 Financial ResultsPain Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 7:57 AM
Pain Therapeutics reports 3Q lossPain Therapeutics reports 3Q loss
finance.yahoo.com - November 2 at 7:57 AM
Health Care Sector Update for 10/30/2017: PTIE,CRME,COM.TO,PSTI - NasdaqHealth Care Sector Update for 10/30/2017: PTIE,CRME,COM.TO,PSTI - Nasdaq
www.nasdaq.com - October 31 at 8:16 AM
Pain Therapeutics Announces Upcoming Meeting with FDA - GlobeNewswire (press release)Pain Therapeutics Announces Upcoming Meeting with FDA - GlobeNewswire (press release)
globenewswire.com - October 31 at 8:16 AM
Pain Therapeutics Announces Upcoming Meeting with FDAPain Therapeutics Announces Upcoming Meeting with FDA
finance.yahoo.com - October 31 at 8:16 AM
Analysts Set Expectations for Pain Therapeutics FY2017 Earnings (PTIE)Analysts Set Expectations for Pain Therapeutics' FY2017 Earnings (PTIE)
www.americanbankingnews.com - October 30 at 2:56 AM
Pain Therapeutics (PTIE) Announces Successful Phase I Clinical Study for PTI-125 to Treat ADPain Therapeutics (PTIE) Announces Successful Phase I Clinical Study for PTI-125 to Treat AD
www.streetinsider.com - October 25 at 9:30 AM
Pain Therapeutics Inc. (PTIE) Is Climbing On Phase 1 Study ResultsPain Therapeutics Inc. (PTIE) Is Climbing On Phase 1 Study Results
www.rttnews.com - October 25 at 9:30 AM
Pain Therapeutics Alzheimers candidate PTI-125 shows encouraging action in early-stage study; shares ahead 14% premarketPain Therapeutics' Alzheimer's candidate PTI-125 shows encouraging action in early-stage study; shares ahead 14% premarket
seekingalpha.com - October 25 at 9:30 AM
Pain Therapeutics, Inc. (PTIE) Shares Fire Up To The Roof; Here’s WhyPain Therapeutics, Inc. (PTIE) Shares Fire Up To The Roof; Here’s Why
finance.yahoo.com - October 25 at 9:30 AM
Todays Research Reports on Stocks to Watch: Pain Therapeutics and Ionis PharmaceuticalsToday's Research Reports on Stocks to Watch: Pain Therapeutics and Ionis Pharmaceuticals
finance.yahoo.com - October 25 at 9:30 AM
Tuesdays Biggest Stock Mover: Pain Therapeutics A Pleasure For InvestorsTuesday's Biggest Stock Mover: Pain Therapeutics A Pleasure For Investors
feeds.benzinga.com - October 24 at 2:31 PM
Pain Therapeutics (PTIE) Announces Successful Phase I Clinical Study for PTI-125 to Treat AD - StreetInsider.comPain Therapeutics (PTIE) Announces Successful Phase I Clinical Study for PTI-125 to Treat AD - StreetInsider.com
www.streetinsider.com - October 24 at 8:56 AM
Pain Therapeutics Announces Successful Phase I Clinical Study for PTI-125Pain Therapeutics Announces Successful Phase I Clinical Study for PTI-125
finance.yahoo.com - October 24 at 8:56 AM
Pain Therapeutics Announces Successful Phase I Clinical Study for PTI-125Pain Therapeutics Announces Successful Phase I Clinical Study for PTI-125
finance.yahoo.com - October 24 at 8:56 AM
Healthcare Industry Trends And Its Impact On Pain Therapeutics Inc (PTIE)Healthcare Industry Trends And Its Impact On Pain Therapeutics Inc (PTIE)
finance.yahoo.com - October 21 at 8:26 AM
Reviewing Recro Pharma (REPH) and Pain Therapeutics (PTIE)Reviewing Recro Pharma (REPH) and Pain Therapeutics (PTIE)
www.americanbankingnews.com - October 16 at 10:30 AM
Pain Therapeutics (PTIE) Set to Announce Earnings on WednesdayPain Therapeutics (PTIE) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 11 at 2:44 AM
How Should You Think About Pain Therapeutics Inc’s (PTIE) Risks?How Should You Think About Pain Therapeutics Inc’s (PTIE) Risks?
finance.yahoo.com - October 5 at 10:57 PM
Pain Therapeutics Leaps on Federal GrantsPain Therapeutics Leaps on Federal Grants
www.baystreet.ca - September 19 at 6:52 AM
Pain Therapeutics nabs $2.2M NIDA grant; shares ahead 12% premarketPain Therapeutics nabs $2.2M NIDA grant; shares ahead 12% premarket
seekingalpha.com - September 19 at 6:51 AM
National Institute on Drug Abuse Awards Pain Therapeutics $2.2 Million GrantNational Institute on Drug Abuse Awards Pain Therapeutics $2.2 Million Grant
finance.yahoo.com - September 19 at 6:51 AM
NIH Awards $1.8 Million Research Grant to Pain Therapeutics in Support of a Blood-based Diagnostic for Alzheimer’s DiseaseNIH Awards $1.8 Million Research Grant to Pain Therapeutics in Support of a Blood-based Diagnostic for Alzheimer’s Disease
finance.yahoo.com - September 19 at 6:51 AM
Contrasting Rigel Pharmaceuticals (RIGL) and Pain Therapeutics (PTIE)Contrasting Rigel Pharmaceuticals (RIGL) and Pain Therapeutics (PTIE)
www.americanbankingnews.com - September 2 at 8:28 PM
Pain Therapeutics (PTIE) Posts  Earnings Results, Misses Expectations By $0.17 EPSPain Therapeutics (PTIE) Posts Earnings Results, Misses Expectations By $0.17 EPS
www.americanbankingnews.com - August 10 at 9:52 PM
Pain Therapeutics Reports Q2 2017 Financial Results And Mid-year Corporate UpdatePain Therapeutics Reports Q2 2017 Financial Results And Mid-year Corporate Update
finance.yahoo.com - August 10 at 7:08 AM
Pain Therapeutics reports 2Q lossPain Therapeutics reports 2Q loss
finance.yahoo.com - August 10 at 7:08 AM
Pain Therapeutics (PTIE) Reports FDA Clearance of Investigational ... - StreetInsider.comPain Therapeutics (PTIE) Reports FDA Clearance of Investigational ... - StreetInsider.com
www.streetinsider.com - August 1 at 4:03 AM
Pain Therapeutics Announces FDA Has Cleared an Investigational New Drug (IND) Application for PTI-125Pain Therapeutics Announces FDA Has Cleared an Investigational New Drug (IND) Application for PTI-125
finance.yahoo.com - August 1 at 4:03 AM
Pain Therapeutics (PTIE) to Post FY2017 Earnings of ($2.35) Per Share, Gabelli ForecastsPain Therapeutics (PTIE) to Post FY2017 Earnings of ($2.35) Per Share, Gabelli Forecasts
www.americanbankingnews.com - July 19 at 10:55 AM
Pain Therapeutics (PTIE) to Release Earnings on MondayPain Therapeutics (PTIE) to Release Earnings on Monday
www.americanbankingnews.com - July 13 at 8:34 PM
Breakfast Technical Briefing on Biotech Stocks -- Opko Health, Pain Therapeutics, Trevena, and Dynavax Technologies - PR Newswire (press release)Breakfast Technical Briefing on Biotech Stocks -- Opko Health, Pain Therapeutics, Trevena, and Dynavax Technologies - PR Newswire (press release)
www.prnewswire.com - June 21 at 2:29 AM
NIH Awards $1.7 Million Research Grant to Pain Therapeutics to Study Alzheimers Disease - GlobeNewswire (press release)NIH Awards $1.7 Million Research Grant to Pain Therapeutics to Study Alzheimer's Disease - GlobeNewswire (press release)
globenewswire.com - June 7 at 1:13 AM
Pain Therapeutics Announces Research Publication on Alzheimers Disease - GlobeNewswire (press release)Pain Therapeutics Announces Research Publication on Alzheimer's Disease - GlobeNewswire (press release)
www.globenewswire.com - June 1 at 8:33 PM
Antibe Therapeutics Engages Topstone Research and Appoints Dr Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346Antibe Therapeutics Engages Topstone Research and Appoints Dr Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346
www.businesswire.com - May 12 at 8:10 AM
Pain Therapeutics Announces Reverse Stock Split - GlobeNewswire (press release)Pain Therapeutics Announces Reverse Stock Split - GlobeNewswire (press release)
globenewswire.com - May 10 at 11:24 AM
Pain Therapeutics (PTIE) 7-for-1 Reverse Stock Split Effective 05/09 - StreetInsider.comPain Therapeutics (PTIE) 7-for-1 Reverse Stock Split Effective 05/09 - StreetInsider.com
www.streetinsider.com - May 10 at 11:24 AM
Pain Therapeutics (PTIE) Surges Following Positive REMOXY Regulatory GuidancePain Therapeutics (PTIE) Surges Following Positive REMOXY Regulatory Guidance
www.streetinsider.com - March 21 at 7:09 PM
PTIE Surges After-hours, Valeant Gets FDA Date, JAZZ Hits Right NotesPTIE Surges After-hours, Valeant Gets FDA Date, JAZZ Hits Right Notes
www.nasdaq.com - March 21 at 10:46 AM
Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE, EGLT)Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE, EGLT)
www.investopedia.com - March 21 at 10:46 AM
PAIN THERAPEUTICS INC Files SEC form 8-K, Other EventsPAIN THERAPEUTICS INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 21 at 10:46 AM
Pain Therapeutics sets path for resubmitting NDA for pain med REMOXY ER; shares up 65% premarketPain Therapeutics sets path for resubmitting NDA for pain med REMOXY ER; shares up 65% premarket
seekingalpha.com - March 21 at 7:43 AM
Pain Therapeutics Announces Positive Regulatory Guidance for REMOXY™ ERPain Therapeutics Announces Positive Regulatory Guidance for REMOXY™ ER
feeds.benzinga.com - March 20 at 7:54 PM
PAIN THERAPEUTICS INC Files SEC form 10-K, Annual ReportPAIN THERAPEUTICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 7 at 7:15 PM
Pain Therapeutics finance chief bids adieuPain Therapeutics finance chief bids adieu
seekingalpha.com - February 18 at 6:29 PM
Pain Therapeutics Reports 2016 Financial ResultsPain Therapeutics Reports 2016 Financial Results
us.rd.yahoo.com - February 18 at 6:29 PM
PAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal OfficersPAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
us.rd.yahoo.com - February 18 at 6:29 PM

Social Media

Financials

Chart

Pain Therapeutics (NASDAQ PTIE) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.